Update, Wed 16 Dec

Download my two educational text books for free using this link: http://159.69.48.3

Includes option for mobile phone friendly version

Hard copy of the Physiology Notes text book on e bay, https://www.ebay.co.uk/itm/-/15402036...

John’s research on text book efficacy, https://journals.sagepub.com/doi/full/10.1177/2158244015612517

UK

Christmas rules

Germany

Deaths, + 935

Schools

Non-essential businesses

until 10 January

One household, four close family members

France

Curfew

Bars and restaurants closed until 20 January

Spain

https://www.theguardian.com/world/live/2020/dec/15/coronavirus-live-news-netherlands-announces-five-week-lockdown-as-uk-detects-new-covid-strain

10% antibody study shows

N = 51,400

Second half of November

Raquel Yotti, Carlos III health institute

One in 10 people living in Spain would have been infected ... half during the first wave and the other half during this second epidemic wave

Madrid, 18.6%

Previous results of the study - published in July after testing nearly 70,000 people in

April-June, prevalence 5.2 %.

Deaths, + 388 = 48,401

Positive test results, + 10,328 = 1,762,212

Population = 47 million

Cases, 4.7 million

CFR = 2.7%

IFR = 1.02%

Moderna / NIH

Food and Drug Administration scientists

https://www.fda.gov/media/144434/download

54 page document

Two-shot regimen was highly effective, 94%

Prevents infections and symptoms

No serious safety concerns

Friday, 18th

General Gustave Perna

Cambridge, Massachusetts, "vast majority"

Preparing to ship almost 6 million doses

3,285 locations in the first week

US, 20 million then 200 million

It will be a very similar cadence that was executed this week with Pfizer, where we’re hitting initial sites on Monday, follow on Tuesday and Wednesday

Canada, 168,000 this year, 56 million by March

UK, 7 million

European Union, 80m + 80m

Japan, 50m

South Korea, 20m

Switzerland, 7.5m

Vaccine progress

MHRA, 1

137,000 in first week

FDA, 2

HC, 1

EMA, 0

Second peer reviewed vaccine study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=featured_home

Ongoing multinational

Placebo-controlled, observer-blinded, randomised, efficacy trial

16 years or older

One to one

Two doses, 21 days apart

Placebo or the BNT162b2 vaccine

30 μg per dose

Lipid nanoparticle

Modified RNA vaccine

Encodes a membrane-anchored SARS-CoV-2 full-length spike protein

n = 43,448 received injections

BNT162b2 group, n = 21,720

8 cases of COVID, at least 7 days after the second dose

1 severe

Placebo group, n = 21,782

162 cases

9 severe

95% (90.3 to 97.6)

October 9

N = 37,706 with at least 2 months of safety data

49% were female,

83% were white,

9% were Black or African American,

28% were Hispanic or Latino

35% were obese, of at least 30.0

21% had at least one coexisting condition

Median age, 52 years

42% older than 55 years

Safety profile

Short-term, mild-to-moderate pain at the injection site, fatigue, and headache

Safety over a median of 2 months was similar to that of other viral vaccines.

Systemic events, most common after 2nd dose

Resolved after 1 – 2 days

Fatigue and headache, 55%

Placebo fatigue and headache, 23%

Fever, mostly after 2nd dose

Temperature, equal or greater than 38°C

16% of younger recipients

11% of older recipients

Incidence of serious adverse events was low and was similar in the vaccine and placebo groups

No stopping rules were met

Видео Update, Wed 16 Dec канала Dr. John Campbell